Daily Sepsis Research Analysis
Mechanistic and translational advances in sepsis research span from circadian–immune regulation of liver injury to repurposing ion transport inhibition for DIC, alongside a small double-blind RCT suggesting adjunctive benefits of Xuebijing plus levosimendan. Collectively, these studies highlight novel targets and combination strategies that modulate inflammation, coagulation, endothelium, and organ dysfunction.
Summary
Mechanistic and translational advances in sepsis research span from circadian–immune regulation of liver injury to repurposing ion transport inhibition for DIC, alongside a small double-blind RCT suggesting adjunctive benefits of Xuebijing plus levosimendan. Collectively, these studies highlight novel targets and combination strategies that modulate inflammation, coagulation, endothelium, and organ dysfunction.
Research Themes
- Circadian-immune regulation in sepsis-associated organ dysfunction
- Drug repurposing and ion transport targets in DIC
- Adjunctive combination therapy modulating coagulation and endothelium
Selected Articles
1. Macrophage-specific UBA1 knockout attenuates sepsis-induced liver dysfunction by regulating inflammatory responses via the BMAL1/CLOCK-REV-ERBα axis.
Using CLP-induced sepsis models, macrophage-specific UBA1 deletion mitigated sepsis-associated liver dysfunction by modulating inflammatory responses via the BMAL1/CLOCK–REV-ERBα circadian axis. The study links ubiquitination machinery in macrophages to circadian regulation as a mechanism for organ protection in sepsis.
Impact: Identifies a macrophage UBA1–circadian axis as a mechanistic driver of sepsis liver injury, opening a novel pathway for targeted interventions. It advances understanding of immunometabolic timing in organ dysfunction.
Clinical Implications: While preclinical, targeting UBA1 or circadian regulators in hepatic macrophages could inspire new adjunctive strategies to prevent or attenuate sepsis-associated liver dysfunction.
Key Findings
- Macrophage-specific UBA1 knockout attenuated sepsis-associated liver dysfunction in CLP models.
- Inflammatory responses were regulated via the BMAL1/CLOCK–REV-ERBα axis.
- Links ubiquitination machinery in macrophages to circadian control in sepsis pathophysiology.
Methodological Strengths
- Genetic cell-type–specific knockout approach isolating macrophage effects
- In vivo sepsis (CLP) modeling enabling organ-level phenotyping
Limitations
- Preclinical mouse data; human relevance not established
- Abstract lacks quantitative outcomes and replication details
Future Directions: Validate in human tissues and translational models; test pharmacologic modulation of UBA1/circadian nodes; define temporal therapeutic windows in sepsis.
Macrophages in the liver play an important role in the development of sepsis-associated liver dysfunction (SALD). Ubiquitin-activating enzyme E1 (UBA1) is critically involved in protein degradation and inflammatory diseases. However, whether UBA1 in macrophages participates in the development of SALD remains unknown. Sepsis and acute liver injury mouse models were established by caecal ligation and puncture (CLP) in macrophage-specific UBA1-knockout (UBA1
2. Effects of Xuebijing combined with levosimendan on immune function and coagulation function in sepsis patients with myocardial injury.
In a double-blind RCT of 88 septic patients with myocardial injury, adding Xuebijing to levosimendan improved coagulation, immune, endothelial, and hemodynamic profiles versus levosimendan alone. Broad biomarker improvements suggest potential adjunctive benefits, though hard clinical outcomes were not assessed.
Impact: Provides randomized, blinded evidence that an adjunctive combination can favorably modulate key sepsis pathophysiology axes in myocardial injury. It informs future trials targeting clinical outcomes.
Clinical Implications: Suggests Xuebijing plus levosimendan as a candidate adjunct to optimize coagulation, inflammation, and hemodynamics in septic myocardial injury; requires confirmation with mortality and organ support endpoints.
Key Findings
- Double-blind RCT (n=88) showed greater reductions in PCT, CRP, TNF-α, ET-1, vWF, sTM, PT, APTT, D-dimer, CD8+, cTnI, CK-MB, BNP, and HR with Xuebijing plus levosimendan.
- Increases in NO, VEGF, platelet count, fibrinogen, CD4+, CD4+/CD8+ ratio, MAP, and CVP were larger in the combination group (all P<0.05).
- Adjunctive therapy improved coagulation, immune function, endothelial integrity, and hemodynamics compared with levosimendan alone.
Methodological Strengths
- Double-blind randomized controlled design
- Predefined multimodal biomarker endpoints across coagulation, immune, endothelial, and cardiac domains
Limitations
- Small single-center sample with surrogate biomarker endpoints
- Lack of clinical outcomes (mortality, ventilation/vasopressor-free days)
Future Directions: Conduct multicenter RCTs powered for mortality and organ support outcomes; evaluate timing, dosing, and safety of Xuebijing in diverse sepsis phenotypes.
We aimed to investigate the effects of Xuebijing (XBJ) combined with levosimendan on the immune function and coagulation function in patients with sepsis complicated by myocardial injury. This double-blind, randomized controlled trial involved 88 sepsis patients with myocardial injury, split into control (n = 44, levosimendan plus conventional therapy) and combination (n = 44, control group's treatment plus XBJ injection) groups. Primary outcomes: coagulation parameters [prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count (PLT), fibrinogen (Fib), and D-dimer (D-D)], immune function indicators (peripheral blood T lymphocyte subsets: CD4+, CD8+, and the CD4+/CD8+ ratio). Secondary outcomes: inflammatory markers [procalcitonin (PCT), C-reactive protein (CRP), and tumor necrosis factor (TNF-α)], vascular endothelial function markers [endothelin-1 (ET-1), nitric oxide (NO), vascular endothelial growth factor (VEGF), von Willebrand factor (vWF), and soluble thrombomodulin (sTM)], myocardial function biomarkers [cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), and B-type brain natriuretic peptide (BNP)], and hemodynamic parameter [heart rate (HR), mean arterial pressure (MAP), and central venous pressure (CVP)]. Post-treatment, serum levels of PCT, CRP, TNF-α, ET-1, vWF, sTM, PT, APTT, D-D, CD8+, cTnI, CK-MB, BNP, and HR were lower in both groups, with further reductions in the combination group. Levels of NO, VEGF, PLT, Fib, CD4+, CD4+/CD8+ ratio, MAP and CVP were higher in the combination group than in the control group (all P < 0.05). The combination of XBJ and levosimendan improves coagulation function, regulates immune function, enhances vascular endothelial function and hemodynamics, reduces inflammation, and alleviates myocardial injury.
3. NKCC1 inhibition as a breakthrough in combating coagulopathy and boosting survival in LPS-induced DIC rat model.
In an LPS-induced DIC rat model, inhibiting NKCC1 with furosemide improved coagulopathy and increased survival, positioning ion transport modulation as a therapeutic strategy in septic coagulopathy. The work highlights drug repurposing potential for an established medication.
Impact: Introduces NKCC1 inhibition as a modifiable target that improves both pathophysiology and survival in septic DIC, enabling rapid translational pathways via repurposing furosemide.
Clinical Implications: Supports evaluating furosemide (as NKCC1 inhibitor) in early-phase clinical studies for septic coagulopathy/DIC, with careful dosing and safety monitoring.
Key Findings
- NKCC1 inhibition with furosemide improved coagulopathy in an LPS-induced DIC rat model.
- Furosemide treatment increased survival compared with controls.
- Positions ion transport modulation as a therapeutic strategy in septic coagulopathy.
Methodological Strengths
- In vivo DIC model with survival as a hard endpoint
- Therapeutic modulation using an approved, well-characterized drug (furosemide)
Limitations
- Preclinical single-species model; human translation uncertain
- Mechanistic pathways beyond NKCC1 inhibition not fully detailed in the abstract
Future Directions: Test NKCC1 inhibition in larger animal models and diverse sepsis phenotypes; design phase 1/2 trials to assess safety, coagulation endpoints, and organ support needs.
Sepsis presents a critical challenge, frequently escalating into a cascade characterized by uncontrolled inflammation, oxidative stress, and coagulopathy. This progression often leads to disseminated intravascular coagulation (DIC) and multiple organ dysfunction syndrome (MODS), both of which are life-threatening conditions. This study focuses on furosemide, a diuretic traditionally known for inhibiting the Na